Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines

References

• NHLBI (National Heart, Lung, and Blood Institute) (US). Global initiative for asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Bethesda (MD): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health; 1995.
   Google Scholar
• GINA. 2017 GINA report: global strategy for asthma management and prevention. 2017 [cited 2017 Oct 05]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
   Google Scholar
• GINA. 2002 GINA report: global strategy for asthma management and prevention. 2002 [cited 2017 Oct 05]. Available from: http://ginasthma.org upon request
   Google Scholar
• GINA. 2006 GINA report: global strategy for asthma management and prevention. 2006 [cited 2017 Oct 05]. Available from: http://ginasthma.org upon request
   Google Scholar
• Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy. 2004;59:469–478.
   PubMed Web of Science ®Google Scholar
• Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034–1037.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.
   PubMed Web of Science ®Google Scholar
• Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124:70–74.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Levy ML. The GINA asthma strategy report: what’s new for primary care? NPJ Prim Care Respir Med. 2015;25:15050.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99.
   PubMed Web of Science ®Google Scholar
• Basheti IA, Qunaibi E, Bosnic-Anticevich SZ, et al. User error with Diskus and Turbuhaler by asthma patients and pharmacists in Jordan and Australia. Respir Care. 2011;56:1916–1923.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938.
   PubMed Web of Science ®Google Scholar
• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report. 2017 [cited 2017 Oct 05]. Available from: http://goldcopd.org/
   Google Scholar
• Reddel HK, Busse WW, Pedersen S, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389:157–166.
   PubMed Web of Science ®Google Scholar
• GINA. 2016 GINA report: global strategy for asthma management and prevention. 2016 [cited 2017 Oct 05]. Available from: http://ginasthma.org upon request
   Google Scholar
• Kew KM, Karner C, Mindus SM, et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;12:CD009019.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007;29:587–595.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;4:CD007313.
   PubMed Web of Science ®Google Scholar
• Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013;1:23–31.
   PubMed Web of Science ®Google Scholar
• Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 2013;1:32–42.
   PubMed Web of Science ®Google Scholar
• Braido F, Baiardini I, Compalati E, et al. Towards the grade of recommendations, assessment, development and evaluation system: methods and results of budesonide/formoterol maintenance and reliever therapy research. Curr Opin Allergy Clin Immunol. 2011;11:361–374.
   PubMed Web of Science ®Google Scholar
• Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med. 1999;160:594–599.
   PubMed Web of Science ®Google Scholar
• Balter M, Ernst P, Watson W, et al. Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working Group. Can Respir J. 2008;15:1B–19B.
   PubMedGoogle Scholar
• Buhl R, Kuna P, Peters MJ, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13:59.
   PubMed Web of Science ®Google Scholar
• Chong J, Haran C, Chauhan BF, et al. Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. Cochrane Database Syst Rev. 2015;7:CD011032.
   PubMed Web of Science ®Google Scholar
• Kew KM, Quinn M, Quon BS, et al. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2016;6:CD007524.
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;5:CD005535.
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;4:CD005533.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129:246–256.
   PubMed Web of Science ®Google Scholar
• Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20:1403–1418.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–136.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368:744–753.
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61:725–736.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Boulet L-P, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007;101:2437–2446.
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Lythgoe D, Jorup C. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J. 2016;48:4903.
   Google Scholar
• Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med. 2009;103:1960–1968.
   PubMed Web of Science ®Google Scholar
• Haughney J, Aubier M, Jørgensen L, et al. Comparing asthma treatment in elderly versus younger patients. Respir Med. 2011;105:838–845.
   PubMed Web of Science ®Google Scholar
• Riemersma RA, Postma D, van der Molen T. Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Prim Care Respir J. 2012;21:50–56.
   PubMedGoogle Scholar
• Louis R, Joos G, Michils A, et al. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract. 2009;63:1479–1488.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, D’Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J. 2005;26:819–828.
   PubMed Web of Science ®Google Scholar
• Sears MR, Boulet L-P, Laviolette M, et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J. 2008;31:982–989.
   PubMed Web of Science ®Google Scholar
• Boonsawat W, Thinkhamrop B. Role of budesonide/formoterol maintenance and reliever therapy: a pragmatic study. Asian Pac J Allergy Immunol. 2014;32:160–165.
   PubMed Web of Science ®Google Scholar
• Lin J, Tang Y, Xiu Q, et al. Real-life effectiveness of budesonide/formoterol therapy in asthma: a subanalysis of the SMARTASIA study. Allergy Asthma Proc. 2016;37:27–34.
   PubMed Web of Science ®Google Scholar
• Zhong N, Lin J, Mehta P, et al. Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study. BMC Pulm Med. 2013;13:1.
   PubMed Web of Science ®Google Scholar
• Loh LC, Lim BK, Raman S, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in moderate-to-severe asthma: a real-life effectiveness study of Malaysian patients. Med J Malaysia. 2008;63:188–192.
   PubMedGoogle Scholar
• Müller V, Gálffy G, Eszes N, et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulm Med. 2011;11:40.
   PubMed Web of Science ®Google Scholar
• Aubier M, Buhl R, Ekstrom T, et al. Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy. Eur Respir J. 2010;36:524–530.
   PubMed Web of Science ®Google Scholar
• Demoly P, Louis R, Søes-Petersen U, et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med. 2009;103:1623–1632.
   PubMed Web of Science ®Google Scholar
• Ställberg B, Naya I, Ekelund J, et al. Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. Int J Clin Pharmacol Ther. 2015;53:447–455.
   PubMed Web of Science ®Google Scholar
• Lin JT, Chen P, Zhou X, et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chin Med J Engl. 2012;125:2994–3001.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol. 2010;125:600–608,608.e1–608.e6.
   PubMed Web of Science ®Google Scholar
• Aalbers R, Backer V, Kava TTK, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin. 2004;20:225–240.
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Le Roux P, Bjåmer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006;130:1733–1743.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Sears MR, Boulet L-P, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J. 2003;10:427–434.
   PubMedGoogle Scholar
• Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011;12:38.
   PubMed Web of Science ®Google Scholar
• Ställberg B, Olsson P, Jörgensen LA, et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract. 2003;57:656–661.
   PubMed Web of Science ®Google Scholar
• Canonica G. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm Pharmacol Ther. 2004;17:239–247.
   PubMed Web of Science ®Google Scholar
• Selroos O. A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid. Ther Clin Risk Manag. 2007;3:349–359.
   PubMedGoogle Scholar
• Price D, Wirén A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy. 2007;62:1189–1198.
   PubMed Web of Science ®Google Scholar
• Miller E, FitzGerald JM. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies – a Canadian economic evaluation. Can J Clin Pharmacol. 2008;15:e165–176.
   PubMedGoogle Scholar
• Baddar S, Jayakrishnan B, Al-Rawas OA. Asthma control: importance of compliance and inhaler technique assessments. J Asthma. 2014;51:429–434.
   PubMed Web of Science ®Google Scholar
• Wu AC, Butler MG, Li L, et al. Primary adherence to controller medications for asthma is poor. Ann Am Thorac Soc. 2015;12:161–166.
   PubMed Web of Science ®Google Scholar
• Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med. 2005;99:1263–1267.
   PubMed Web of Science ®Google Scholar
• Sovani MP, Whale CI, Oborne J, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br J Gen Pract. 2008;58:37–43.
   PubMed Web of Science ®Google Scholar
• Patel M, Pilcher J, Hancox RJ, et al. The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis. NPJ Prim Care Respir Med. 2015;25:14099.
   PubMed Web of Science ®Google Scholar
• Liam C-K, Pang Y-K, Chua K-T. Satisfaction level and asthma control among Malaysian asthma patients on Symbicort Maintenance and Reliever Therapy (SMART) in the primary care setting (SMARTEST study). Asian Pac J Allergy Immunol. 2014;32:145–152.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–1076.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Zhong N, et al. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given “as needed” in mild asthma: study protocols for two randomised controlled trials. Trials. 2017;18:12.
   PubMedGoogle Scholar
• Beasley R, Weatherall M, Shirtcliffe P, et al. Combination corticosteroid/β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol. 2014;133:39–41.
   PubMed Web of Science ®Google Scholar
• Beasley R, Pavord I, Papi A, et al. Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. Eur Respir J. 2016;47:981–984.
   PubMed Web of Science ®Google Scholar
• Efficacy of LAMA added to ICS in treatment of asthma. 2017 [cited 2017 Oct 05]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02296411
   Google Scholar
• Lee LA, Yang S, Kerwin E, et al. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med. 2015;109:54–62.
   PubMed Web of Science ®Google Scholar
• Jabbal S, Manoharan A, Lipworth BJ. Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma. Clin Exp Allergy. 2017;47:1239–1245.
   PubMed Web of Science ®Google Scholar
• Dwan K, Milan SJ, Bax L, et al. Vilanterol and fluticasone furoate for asthma. Cochrane Database Syst Rev. 2016;9:CD010758.
   PubMedGoogle Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Ferrando M, Varricchi G, et al. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170:122–131.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–796.
   PubMed Web of Science ®Google Scholar
• Hall IP, Fowler AV, Gupta A, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37–44.
   PubMed Web of Science ®Google Scholar
• Kuna P, Bjermer L, Tornling G. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma. Drug Des Devel Ther. 2016;10:2759–2770.
   PubMed Web of Science ®Google Scholar
• Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4:699–707.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Guerreros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017;50:1700670.
   PubMed Web of Science ®Google Scholar
• Krug N, Hohlfeld JM, Kirsten A-M, et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015;372:1987–1995.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet L-P, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–2110.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936–946.
   PubMed Web of Science ®Google Scholar
• van der Palen J, Klein JJ, Kerkhoff AH, et al. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient Educ Couns. 1997;32:S87–95.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003;1:CD001117.
   PubMedGoogle Scholar
• Guevara JP, Wolf FM, Grum CM, et al. Effects of educational interventions for self management of asthma in children and adolescents: systematic review and meta-analysis. BMJ. 2003;326:1308.
   PubMed Web of Science ®Google Scholar
• Thomas M, Bateman E. Asthma attacks: how can we reduce the risks? NPJ Prim Care Respir Med. 2015;25:14105.
   PubMed Web of Science ®Google Scholar
• Price D, Fletcher M. van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
   PubMed Web of Science ®Google Scholar
• Price D, David-Wang A, Cho S-H, et al. Time for a new language for asthma control: results from REALISE Asia. J Asthma Allergy. 2015;8:93–103.
   PubMed Web of Science ®Google Scholar
• Boulet L-P, Vervloet D, Magar Y, et al. Adherence: the goal to control asthma. Clin Chest Med. 2012;33:405–417.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Powell H, Coughlan J, et al. Limited (information only) patient education programs for adults with asthma. Cochrane Database Syst Rev. 2002;2:CD001005.
   PubMedGoogle Scholar
• Reddel HK, Barnes DJ. Exacerbation advisory panel. Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J. 2006;28:182–199.
   PubMed Web of Science ®Google Scholar
• Boyter AC, Ford NH, Zlotos L. Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the U.K. Respir Med. 2011;105:864–868.
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Boudiaf N, Stempel DA, et al. The frequency of, and adherence to, single maintenance and reliever therapy instructions in asthma: a descriptive analysis. NPJ Prim Care Respir Med. 2016;26:16038.
   PubMed Web of Science ®Google Scholar
• Czarnecka K, Chapman KR. The clinical impact of single inhaler therapy in asthma. Clin Exp Allergy. 2012;42:1006–1013.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Anto JM, Akdis M, et al. Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story. Allergy. 2016;71:1513–1525.
   PubMed Web of Science ®Google Scholar